Gastroenterology · Phase 2-3 · pulled 2026-11-06

Ulcerative colitis: trial sites and investigators

25 sites and 10 investigators from 183 completed and terminated Phase 2-3 trials of ulcerative colitis (last 12 years), plus 128 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Ulcerative colitis: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Nzoz Vivamed Warsaw, Poland · 18 spellings merged	25 21 completed, 4 terminated	NCT02914535 NCT05507203 NCT03524092 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15 NCT03283085 A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) completed 2023-12-13	2026-09-08	9 NCT06937086 NCT05242484 NCT06651281 NCT06588855	94
2	Semmelweis Egyetem Budapest, Hungary · 18 spellings merged	25 22 completed, 3 terminated	NCT05767021 NCT06049017 NCT05370885 6 trials with titles NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-04-27 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25	2026-04-27	15 NCT03950232 NCT06937086 NCT07483073 NCT07186101	94
3	Spitalul Clinic Colentina Bucharest, Romania · 6 spellings merged	24 17 completed, 7 terminated	NCT05611671 NCT02914535 NCT05507216 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT05672199 Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis terminated 2024-10-31 Stop reason on the record: “The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated.” NCT04987307 Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis terminated 2024-10-22 Stop reason on the record: “The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.”	2026-09-21	9 NCT06937086 NCT07186101 NCT07577856 NCT07196748	89
4	Hepato-Gastroenterologie HK, s.r.o. Hradec Králové, Czechia · 15 spellings merged	24 20 completed, 4 terminated	NCT05767021 NCT06049017 NCT05507203 6 trials with titles NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-04-27 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT06137183 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) terminated 2025-06-16 Stop reason on the record: “Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.” NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT04987307 Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis terminated 2024-10-22 Stop reason on the record: “The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.”	2026-04-27	13 NCT03950232 NCT07415044 NCT06937086 NCT06651281	88
5	CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC Kharkiv, Ukraine · 18 spellings merged	23 20 completed, 3 terminated	NCT02914535 NCT03524092 NCT04882007 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT04882007 Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis completed 2025-01-28 NCT04469686 Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories completed 2024-09-19 NCT04607837 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis completed 2024-06-19 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12	2026-09-08	3 NCT03950232 NCT04033445 NCT03519945	95
6	Istituto Clinico Humanitas Rozzano, Italy · 12 spellings merged	22 18 completed, 4 terminated	NCT05611671 NCT02914535 NCT05767021 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-04-27 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT06137183 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) terminated 2025-06-16 Stop reason on the record: “Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.”	2026-09-21	15 NCT07415044 NCT06937086 NCT07483073 NCT07186101	93
7	Kyiv City Clinical Hospital #18 Kyiv, Ukraine · 15 spellings merged	22 18 completed, 4 terminated	NCT02914535 NCT05370885 NCT05507203 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT04607837 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis completed 2024-06-19 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15	2026-09-08	0	93
8	Charité Campus Virchow-Klinikum Berlin, Germany · 27 spellings merged	21 19 completed, 2 terminated	NCT05611671 NCT02914535 NCT05507216 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) completed 2025-06-05 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17	2026-09-21	13 NCT03950232 NCT07483073 NCT07186101 NCT05242484	96
9	Shaare Zedek Medical Center Jerusalem, Israel · 6 spellings merged	21 19 completed, 2 terminated	NCT05611671 NCT02914535 NCT05784246 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis completed 2026-05-01 NCT03196427 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) completed 2025-07-17 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01	2026-09-21	18 NCT03950232 NCT06937086 NCT07483073 NCT05528510	90
10	Twoja Przychodnia-Szczecinskie Centrum Medyczne Szczecin, Poland · 11 spellings merged	21 18 completed, 3 terminated	NCT05611671 NCT02914535 NCT05784246 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis completed 2026-05-01 NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-04-27 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis terminated 2025-05-30 Stop reason on the record: “Sponsor Decision\_Not Safety Related”	2026-09-21	15 NCT03950232 NCT05528510 NCT05242484 NCT04033445	93
11	UZ Leuven Leuven, Belgium · 14 spellings merged	21 19 completed, 2 terminated	NCT05784246 NCT05767021 NCT04883840 6 trials with titles NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis completed 2026-05-01 NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-04-27 NCT04883840 Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis terminated 2025-10-11 Stop reason on the record: “Due to the university's termination of its contract with the online questionnaire platform, we decided to discontinue the study before reaching the anticipated sample size.” NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) completed 2025-06-05	2026-05-01	13 NCT06937086 NCT07483073 NCT05242484 NCT06260163	91
12	CHU Nice - Hôpital de l'Archet 2 Nice, France · 18 spellings merged	20 17 completed, 3 terminated	NCT05611671 NCT02914535 NCT06049017 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT06137183 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) terminated 2025-06-16 Stop reason on the record: “Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.” NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17	2026-09-21	14 NCT03950232 NCT06937086 NCT05528510 NCT05242484	91
13	Debreceni Egyetem Klinikai Kozpont Debrecen, Hungary · 6 spellings merged	20 18 completed, 2 terminated	NCT02914535 NCT06049017 NCT03196427 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT03196427 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) completed 2025-07-17 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) completed 2025-06-05 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17	2026-09-08	2 NCT04033445 NCT07196748	95
14	Endoskopia Sp. z o.o. Sopot, Poland · 11 spellings merged	20 14 completed, 6 terminated	NCT02914535 NCT05370885 NCT05785715 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis terminated 2025-05-30 Stop reason on the record: “Sponsor Decision\_Not Safety Related” NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15 NCT03283085 A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) completed 2023-12-13 NCT03341962 Phase 2 Dose-finding IMU-838 for Ulcerative Colitis terminated 2022-11-16 Stop reason on the record: “Considering the efficacy results of the induction phase (allowed use of corticosteroids as concomitant medication) in the study population and since IMU-838 did not show superiority over placebo, the ”	2026-09-08	12 NCT03950232 NCT05242484 NCT04033445 NCT07196748	88
15	Pannonia Maganorvosi Centrum Budapest, Hungary · 6 spellings merged	20 17 completed, 3 terminated	NCT05767021 NCT06049017 NCT05370885 6 trials with titles NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-04-27 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT04607837 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis completed 2024-06-19 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12	2026-04-27	10 NCT03950232 NCT07186101 NCT05242484 NCT07577856	87
16	Whipps Cross University Hospital London, United Kingdom · 14 spellings merged	20 17 completed, 3 terminated	NCT06049017 NCT05370885 NCT03196427 6 trials with titles NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT03196427 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) completed 2025-07-17 NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) completed 2025-06-05	2026-01-05	12 NCT03950232 NCT06937086 NCT06651281 NCT07196748	92
17	Centrum Zdrowia MDM Warsaw, Poland · 5 spellings merged	19 16 completed, 3 terminated	NCT02914535 NCT06137183 NCT03524092 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT06137183 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) terminated 2025-06-16 Stop reason on the record: “Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.” NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT04607837 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis completed 2024-06-19 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15	2026-09-08	10 NCT03950232 NCT06651281 NCT05287126 NCT06979336	95
18	Korczowski Bartosz, Gabinet Lekarski Rzeszów, Poland · 7 spellings merged	19 16 completed, 3 terminated	NCT02914535 NCT05784246 NCT03196427 6 trials with titles NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis completed 2026-05-01 NCT03196427 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) completed 2025-07-17 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01 NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) completed 2025-06-05	2026-09-08	12 NCT06937086 NCT06663332 NCT06260163 NCT06865417	89
19	AKH - Medizinische Universität Wien Vienna, Austria · 12 spellings merged	18 16 completed, 2 terminated	NCT05611671 NCT02914535 NCT05507203 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15 NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis terminated 2023-12-20 Stop reason on the record: “Due to futility”	2026-09-21	7 NCT06937086 NCT07186101 NCT04844606 NCT06052059	91
20	Kyungpook National University Hospital Daegu, South Korea · 9 spellings merged	18 15 completed, 3 terminated	NCT05784246 NCT04779307 NCT05507203 6 trials with titles NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis completed 2026-05-01 NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01 NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT04607837 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis completed 2024-06-19 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15	2026-05-01	8 NCT03950232 NCT07415044 NCT06405087 NCT03596645	88
21	Lexmedica Wroclaw, Poland · 5 spellings merged	18 17 completed, 1 terminated	NCT03524092 NCT02620046 NCT03518086 6 trials with titles NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15 NCT03283085 A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) completed 2023-12-13 NCT04023396 Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis completed 2023-02-23 NCT03945188 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis completed 2022-02-16	2025-02-17	2 NCT05177835 NCT03519945	97
22	Texas Digestive Disease Consultants Southlake, United States · 13 spellings merged	17 13 completed, 4 terminated	NCT07222189 NCT06867094 NCT02914535 6 trials with titles NCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) terminated 2026-10-15 Stop reason on the record: “Business decision” NCT06867094 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis terminated 2026-10-12 Stop reason on the record: “Business decision” NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis terminated 2025-05-30 Stop reason on the record: “Sponsor Decision\_Not Safety Related” NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15	2026-10-15	9 NCT05242484 NCT06651281 NCT07196748 NCT07184996	94
23	Gastro I, s.r.o. Prešov, Slovakia · 15 spellings merged	17 15 completed, 2 terminated	NCT05611671 NCT05507216 NCT03524092 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 completed 2025-07-15 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT04987307 Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis terminated 2024-10-22 Stop reason on the record: “The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.” NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12 NCT03518086 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) completed 2024-05-15	2026-09-21	11 NCT03950232 NCT07415044 NCT06937086 NCT05242484	89
24	Mater Hospital Brisbane South Brisbane, Australia · 13 spellings merged	17 14 completed, 3 terminated	NCT05611671 NCT02914535 NCT05370885 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis completed 2026-09-08 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 completed 2025-06-25 NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis completed 2025-02-17 NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease completed 2024-06-12	2026-09-21	11 NCT07158242 NCT05242484 NCT04033445 NCT06663332	94
25	WIP Warsaw IBD Point Profesor Kierkus Warsaw, Poland · 19 spellings merged	17 12 completed, 5 terminated	NCT05611671 NCT05784246 NCT06049017 6 trials with titles NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC completed 2026-09-21 NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis completed 2026-05-01 NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis completed 2026-01-05 NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis terminated 2025-08-29 Stop reason on the record: “Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary” NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) completed 2025-07-01 NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) completed 2025-06-05	2026-09-21	31 NCT07415044 NCT06937086 NCT07483073 NCT07186101	90

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Ulcerative colitis: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Severine Vermeire UZ Leuven, Belgium	4	NCT05507216 NCT05507203 NCT04023396 NCT03760003	PMID 42892326 Journal of the Academy of Nutrition and Dietetics, 2026 · High match PMID 42864953 Journal of Crohn's & colitis, 2026 · High match PMID 42835753 Clinical and experimental gastroenterology, 2026 · High match
2	Christa S Zerbe National Institute of Allergy and Infectious Diseases (NIAID)	2	NCT05104723 NCT03983837	PMID 33813069 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022 · High match
3	Bruce Sands Mount Sinai Health System Digestive Disease Institute, New York USA	2	NCT05507216 NCT05507203	PMID 35765683 ACG case reports journal, 2022 · High match PMID 30726913 Inflammatory bowel diseases, 2020 · High match PMID 30666957 eLife, 2020 · High match
4	Raja Atreya Friedrich-Alexander University Erlangen-Nuremberg	2	NCT04985968 NCT03178669	PMID 42836101 Crohn's & colitis 360, 2026 · High match PMID 42774300 Frontiers in digital health, 2026 · High match PMID 42631819 Clinical pharmacokinetics, 2026 · High match
5	Sidhartha Sinha Stanford University	1	NCT03724175	No paper matched at High or Medium confidence
6	Calum D Moulton King's College London	1	NCT06309472	No paper matched at High or Medium confidence
7	Severine Vermeire KU/UZ Leuven	1	NCT04883840	PMID 42892326 Journal of the Academy of Nutrition and Dietetics, 2026 · High match PMID 42864953 Journal of Crohn's & colitis, 2026 · High match PMID 42835753 Clinical and experimental gastroenterology, 2026 · High match
8	Azita Hekmatdoost Shahid Beheshti University of Medical Sciences	1	NCT06351696	PMID 42064684 Current therapeutic research, clinical and experimental, 2026 · High match PMID 38877032 Scientific reports, 2024 · High match PMID 38500985 Heliyon, 2024 · High match
9	Per M Hellström Uppsala University Hospital	1	NCT05118919	No paper matched at High or Medium confidence
10	Petr Hrúz Clarunis	1	NCT04991324	PMID 39683589 Nutrients, 2024 · High match PMID 39246002 United European gastroenterology journal, 2025 · High match PMID 38095254 Therapeutische Umschau. Revue therapeutique, 2023 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.